[1] Salzman NH, Hung K, Haribhai D, Chu H, Karlsson -Sjöberg J, Amir E, Teggatz P, Barman M, Hayward M, Eastwood D, Stoel M, Zhou Y, Sodergren E, Weinstock GM, Bevins CL, Williams CB, Bos NA. Enteric defensins are essential regulators of intestinal microbia l ecology. Nat. Immunol., 11, 76 –83 (2010).
[2] Lu W, de Leeuw E. Pro-inflammatory and pro-apoptotic properties of Human Defensin 5. Biochem. Biophys. Res. Commun., 436, 557 –562 (2013).
[3] Zhao A, Lu W, de Leeuw E. Functional synergism of Human Defensin 5 and Human Defensin 6. Biochem. Biophys. Res. Commun., 467, 967 –972 (2015).
[4] Kelvin DJ, Michiel DF, Johnston JA, Lloyd AR, Sprenger H, Oppenheim JJ, Wang JM. Chemokines and serpentines: The molecular biology of chemokine receptors. J. Leukoc. Biol. , 54, 604-612 (1993).
[5] Holmes WE, Lee J, Kuang WJ, Rice G C, Wood W I. Structure and functional expression of a human interleukin-8 receptor. Science, 253, 1278-1280 (1991).
[6] Murphy PM, Tiffany HL. Cloning of complementary DNA encoding a functional human intefleukin-8 receptor. Science, 253, 1280-1283 (1991).
[7] Lee J, Horuk R, Rice GC, et al. Characterization of two high affinity human interleukin-8 receptors. J. Biol. Chem., 267, 16283-16287 (1992).
[8] Gayle RB 3d, Sleath PR, Srinivason S, et al. Importance of the amino terminus of the interleukin-8 receptor in ligand interactions. J. Biol. Chem. , 268, 7283-7289 (1993).
[9] Wehkamp J, Salzman NH, Porter E, Nuding S, Weichenthal M, Petras RE, Shen B, Schaeffeler E, Schwab M, Linzmeier R, Feathe rs RW, Chu H, Lima HJ, Fellermann K, Ganz T, Stange EF, Bevins CL. Reduced Paneth cell α-defensins in ileal Crohn’s disease. Proc. Natl. Acad. Sci. U. S. A., 102, 18129 –18134 (2005).
[10] Elphick D, Liddell S, Mahida YR. Impaired luminal processing of hum an defensin-5 in Crohn’s disease: Persistence in a complex with chymotrypsinogen and trypsin. Am. J. Pathol., 172, 702 –713 (2008).
[11] Takahashi N, Kobayashi M, Ogura J, Yamaguchi H, Satoh T, Watanabe K, Iseki K. Immunoprotective effect of epigallocatech in-3-gallate on oral anticancer drug-induced α-defensin reduction in Caco-2 cells. Biol. Pharm. Bull., 37, 490 – 492 (2014).
[12] Takano M, Yumoto R, Murakami T. Expression and function of efflux drug transporters in the intestine. Pharmacol . Ther., 109,137-161(2006).
[13] Wessler JD, Grip L T, Mendell J, Giugliano RP. The P -glycoprotein transport system and cardiovascular drugs. J . Am. Coll. Cardiol., 61, 2495-2502 (2013).
[14] Ristic B, Sikder MOF, Bhutia YD, Ganapathy V. Pharmacologic inducers o f the uric acid exporter ABCG2 as potential drugs for treatment of gouty arthritis. Asian. J. Pharm. Sci., 15, 173-180 (2020).
[15] Rege BD, Kao JP Y, Polli JE. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur. J. Pharm. Sci., 16, 237-246 (2002).
[16] Taipalensuu J, Törnblom H, Lindberg G, Einarsson C, Sjöqvist F, Melhus H, Garberg P, Sjöström B, Lundgren B, Artursson P. Correlation of gene expression of ten drug efflux proteins of the ATP -binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco -2 cell monolayers. J. Pharmacol. Exp. Ther., 299, 164-170 (2001).
[17] Englund G, Rorsman F, Rönnblom A, Karlbom U, Lazorova L, Gråsjö J, Kindmark A, Artursson P. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur. J. Pharm. Sci., 29, 269-277 (2006).
[18] Matsumoto H, Erickson RH, Gum JR, Yoshioka M, Gum E, Kim YS. Biosynthesis of alkaline phosphatase during differentiation of the human colon cancer cell line Caco-2. Gastroenterology, 98, 1199-1207 (1990).
[19] Laurent F, Eckmann L, Savidge TC, Morgan G, Theodos C, Naciri M, Kagnoff MF. Cryptosporidium parvum infection of human intestinal epithelial cells induces the polarized secretion of C -X-C chemokines. Infect . Immun., 65, 5067–5073 (1997).
[20] Steffansen B, Pedersen MDL, Laghmo ch AM, Nielsen CU. SGLT1-mediated transport in Caco-2 cells is highly dependent on cell bank origin. J. Pharm. Sci., 106, 2664–2670 (2017).
[21] Zhang Z, Feng S. The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials , 27, 4025-4033 (2006).
[22] Dodane V, Khan AM, Merwin JR. Effect of chitosan on epithelial permeability and structure. Int . J. Pharm., 182, 21-32 (1999).
[23] Terada Y, Ogura J, Tsujimoto T, Kuwayama K, Koizumi T, Sasaki S, Maruyama H, Kobayashi M, Yamaguchi H, Iseki K. Intestinal P -glycoprotein expression is multimodally regulated by intestinal ischemia -reperfusion. J. Pharm. Pharm. Sci., 17. 266-276 (2014).
[24] Ogura J, Kuwayama K, Takaya A, Terada Y, Tsujimoto T, Koizumi T, Maruyama H, Fujikawa A, Takahashi N, Kobayashi M, Itagaki S, Hirano T, Yamaguchi H, Iseki K. Intestinal ischemia -reperfusion increases efflux for uric acid via paracellular route in the intestine, but decreases that via transcellular route mediated by BCRP. J . Pharm. Pharm. Sci., 15. 295-304 (2012).
[25] Yang E, Shen J. The roles and functions of Paneth cells in Crohn’s disease: A critical review. Cell. Prolif., e12958 (2020).
[26] Blackwell TS, Christman JW. The role of nuclear factor-kappa B in cytokine gene regulation. Am . J. Respir. Cell. Mol. Biol., 17, 3-9 (1997).
[27] Yasuda G, Kobayashi M, Kubota A, Narumi K, Furugen A, Satoh T, Suzuki N, Iseki K. Analysis of α-defensin 5 secretion in differentiated Caco -2 cells: Comparison of Cell Bank Origin. Biol. Pharm. Bull. , Accepted.
[28] Custodio JM, Wu C, Benet LZ. Predicting drug disposition, absorption/elimination/transpor ter interplay and the role of food on drug absorption. Adv. Drug. Deliv. Rev., 60, 717-733 (2008).
[29] Ebert B, Seidel A, Lampen A. Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco -2 cells and its induction by Ah-receptor agonists. Carcinogenesis , 26, 1754-1763 (2005).
[30] Brand W, Schutte ME, Williamson G, Zanden JJ, Cnubben NHP, Gr oten JP, Bladeren PJ, Rietjens IMCM. Flavonoid -mediated inhibition of intestinal ABC transporters may affect the oral bioavailability of drugs, food -borne toxic compounds and bioactive ingredients. Biomed . Pharmacother., 60, 508-519 (2006).
[31] Shimizu M. Interaction between food substances and the intestinal epithelium. Biosci. Biotechnol. Biochem., 74, 232-241 (2010).
[32] Wagner D, Spahn-Langguth H, Hanafy A, Koggel A, Langguth P. Intestinal drug efflux: formulation and food effects. Adv. Drug. Deliv. Rev., 50, S13-S31 (2001).
[33] Hung TV, Suzuki T. Short -Chain Fatty Acids Suppress Inflammatory Reactions in Caco-2 Cells and Mouse Colons. J. Agric. Food. Chem., 66, 108-117 (2018).
[34] Kovacs-Nolan J, Zhang H, Ibuki M, Nakamori T, Yoshiura K, Turner P V, Matsui T, Mine Y. The PepT1-transportable soy tripeptide VPY reduces intestinal inflammation. Biochim . Biophys. Acta, 1820, 1753-63 (2012).
[35] Ogura J, Kobayashi M, Itagaki S, Hirano T, Iseki K. Alteration of Mrp2 and P-gp expression, including expression in remote organs after intestinal ischemia reperfusion. Life. Sci., 82. 1242-1248 (2008).
[36] Jing W, Safarpour Y, Zhang T, Guo P, Chen G, Wu X, Fu Q, Wang Y. Berberine Upregulates P-Glycoprotein in Human Caco-2 Cells and in an Experimental Model of Colitis in the Rat via Activation of Nrf2 -Dependent Mechanisms. J. Pharmacol. Exp. Ther., 366, 332-340 (2018).
[37] Störmer E, Perloff MD, Moltke LL, Greenblatt DJ. Methadone Inhibits Rhodamine123 Transport in Caco -2 Cells. Drug. Metab. Dispos., 29, 954-956 (2001).
[38] Li L, Fu Q, Xia M, Xin L, Shen H, Li G, Ji G, Meng Q, Xie Y. Inhibition of P-Glycoprotein Mediated Efflux in Caco -2 Cells by Phytic Acid. J . Agric. Food. Chem., 66, 988-998 (2018).
[39] Xie Q, Zhang J, Liu M, Liu P, Wang Z, Zhu L, Jiang L, Jin M, Liu X, Liu L, Liu X. Short-chain fatty acids exert opposite effec ts on the expression and function of p-glycoprotein and breast cancer resistance protein in rat intestine. Acta. Pharmacol. Sin., doi: 10.1038/s41401-020-0402-x (2020).
[40] Zuo J, Zhao M, Liu B, Han X, Li Y, Wang W, Zhang Q, Lv P, Xing L, Shen H, Zhang X. TNF‑α‑mediated upregulation of SOD‑2 contributes to cell proliferation and cisplatin resistance in esophageal squamous cell carcinoma. Oncol. Rep., 42, 1497-1506 (2019).
[41]日本ベーリンガーインゲルハイム株式会社 ,ジオトリフ錠 ®インタビューフォーム, 3 (2020).
[42] Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Caicun Z, Oberdick M, Shahidi M, Yang CH. An irreversible inhibitor of EGFR/HER1 and HER2 + best supportive care (BSC) versus placebo + BSC in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinib or gefitinib (LUX-Lung 1). Ann. Oncol., 21, 1 (2010).
[43] Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Lorence R, Shahidi M, Yang CH. Subgroup Analysis of LUX -Lung 1: A Randomized Phase III Trial of Afatinib (BIBW 2992) + Best Supportive Care (BSC) versus Placebo plus BSC in Patients with NSCLC Failing 1 -2 Lines of Chemotherapy and Erlotinib or Gefitinib. J. Thorac. Oncol., 5, S557-S558 (2010).
[44] Murakami H, Tamura T, Takahashi T, Nokihara H, Naito T, Nakamura Y, Nishio K, Seki Y, Sarashina A, Shahidi M, Yamamoto N. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non -small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX -Lung 4). Cancer. Chemother. Pharmacol., 69, 891-899 (2011).
[45] Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, Munster P, Frakes L, Kelly S, Garcia A A, Cleator S, Uttenreuther FM, Jones H, Wind S, Vinisko R, Hickish T. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2 -positive metastatic breast cancer progressing after trastuzumab. Breast Cancer. Res. Treat., 133, 1057-1065 (2012).
[46] Yang J CH, Reguart N, Barinoff J, Kohler J, Uttenreuther FM, Stammberger U, O'Brien D, Wolf J, Cohen EEW. Diarrhea associated with afatinib: an oral ErbB family blocker. Expert. Rev. Anticancer. Ther., 13, 729–736 (2013).
[47] McConnell EL, Basit AW, Murdan S. Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in‐vivo experiments. J. Pharm. Pharmacol., 60. 63-70 (2008).
[48] Pan D, Jiang C, Ma Z, Blonska M, You M J, Lin X. MALT1 is required for EGFR-induced NF-κB activation and contributes to EGFR-driven lung cancer progression. Oncogene , 35, 919-928 (2016).
[49] Hu X, Shi S, Wang H, Yu X, Wang Q, Jiang S, Ju D, Ye L, Feng M. Blocking autophagy improves the anti -tumor activity of afatinib in lung adenocarcinoma with activating EGFR mutations in vitro and in vivo. Sci . Rep., 7, 4559 (2017).